ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2384

Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort

Bernard Rubin1, Rou Sore1, Melissa Munroe1, Daniele DeFreese1, Adrian Holloway1, Mohan Purushothaman1, Yangfen Li2, Hu Zeng2, Uma Thanarajasingam2, Judith James3 and Eldon Jupe1, 1Progentec Diagnostics, Inc., Oklahoma City, OK, 2Mayo Clinic, Rochester, MN, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: ACR Convergence 2025

Keywords: , , ,

Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by unpredictable disease activity. The Lupus Disease Activity Index (L-DAI) is a blood-based assessment informed by 10 immune biomarkers that objectively measures current disease activity, while the hybrid SLEDAI (hSLEDAI) is a clinician assessed measure of disease activity. This study evaluated the association between both L-DAI and hSLEDAI and patient reported quality of life (HRQol) in a small real-world community-based, prospectively followed SLE cohort.

Methods: We conducted a retrospective analysis from a small cohort of adults with classified SLE longitudinally and serially followed at the Mayo clinic from 2018 to 2021. L-DAI, hSLEDAI were collected quarterly for 12 months but clinicians were blinded to the L-DAI score throughout the study period. HRQol was assessed using the LupusPRO score (0-100 scale) at each visit. Linear regression was used to evaluate the association between HRQol and both L-DAI and hSLEDAI scores.

Results: Among 30 patients contributing to 145 visits, 27 (90%) were female and 3 (10.00%) were male. HRQol ranged from 28 to 100 (mean= 70.79 ± 16.34). In multivariable linear regression, both an increase in hSLEDAI (β = -0.89, p= 0.006) and an increase in L-DAI (β = -0.25, p= 0.020) were independently associated with a lower HRQol.

Conclusion: Our study demonstrated that both L-DAI and hSLEDAI were significantly associated with patient reported HRQol. In fact, an incremental increase in both L-DAI and hSLEDAI correlated with a decrease in patient reported quality of life. These findings highlight the utility of L-DAI and hSLEDAI in assessing disease activity and patient-reported quality of life measures. However, larger, more diverse patient cohorts are needed to validate these findings.

Disclosures: B. Rubin: Progentec Diagnostics, Inc., 3, 4; R. Sore: Progentec Diagnostics, Inc., 3; M. Munroe: Progentec Diagnostics, Inc., 3; D. DeFreese: Progentec Diagnostics, Inc., 3; A. Holloway: Progentec Diagnostics, Inc., 3; M. Purushothaman: Progentec Diagnostics, Inc., 3, 4, 10; Y. Li: None; H. Zeng: None; U. Thanarajasingam: None; J. James: GlaxoSmithKlein(GSK), 2, Progentec, 5; E. Jupe: Progentec Diagnostics, Inc., 3, 4, 10.

To cite this abstract in AMA style:

Rubin B, Sore R, Munroe M, DeFreese D, Holloway A, Purushothaman M, Li Y, Zeng H, Thanarajasingam U, James J, Jupe E. Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/patient-reported-quality-of-life-in-sle-association-with-biomarker-derived-disease-activity-index-l-dai-and-hsledai-in-a-prospective-cohort/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-quality-of-life-in-sle-association-with-biomarker-derived-disease-activity-index-l-dai-and-hsledai-in-a-prospective-cohort/